|
|
|
|
| LEADER |
00000cam a2200000 i 4500 |
| 001 |
SCIDIR_on1343867003 |
| 003 |
OCoLC |
| 005 |
20231120010702.0 |
| 006 |
m o d |
| 007 |
cr |n||||||||| |
| 008 |
220908s2022 mau o 000 0 eng d |
| 040 |
|
|
|a YDX
|b eng
|e rda
|e pn
|c YDX
|d OPELS
|d GZM
|d OCLCQ
|d SFB
|d OCLCO
|d N$T
|
| 020 |
|
|
|a 9780323910378
|q (electronic bk.)
|
| 020 |
|
|
|a 0323910378
|q (electronic bk.)
|
| 020 |
|
|
|z 9780323910361
|
| 020 |
|
|
|z 032391036X
|
| 035 |
|
|
|a (OCoLC)1343867003
|
| 050 |
|
4 |
|a RC375
|
| 082 |
0 |
4 |
|a 616.83
|2 23
|
| 245 |
0 |
4 |
|a The neurobiology of the Gilles De La Tourette syndrome and chronic tics.
|n Part B /
|c Edited by Marc E. Lavoie, Andrea E. Cavanna.
|
| 264 |
|
1 |
|a Cambridge, MA :
|b Academic Press,
|c 2022.
|
| 300 |
|
|
|a 1 online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a International review of movement disorders ;
|v v. 4
|
| 588 |
0 |
|
|a Print version record.
|
| 505 |
0 |
|
|a Intro -- The Neurobiology of the Gilles De La Tourette Syndrome and Chronic Tics: Part B -- Copyright -- Contents -- Contributors -- Preface: Current and cutting-edge research on the neurobiology of the Gilles de la Tourette syndrome -- Section IV: New etiological models: from fundamental neurobiology to applied science -- Chapter One: The genetic basis of Gilles de la Tourette syndrome -- 1. Introduction -- 2. Early studies -- 2.1. Heritability and segregation analysis -- 2.2. Linkage studies -- 2.3. Candidate gene association studies -- 2.4. Chromosomal alterations -- 3. Genome-wide association studies (GWAS) -- 3.1. Polygenic risk -- 4. Rare variation in TS -- 4.1. Single-nucleotide and indel variants -- 4.2. Copy number variation -- 5. Pathway analysis -- 6. Epigenetic studies -- 7. Cross-disorder analysis -- 8. Conclusions and questions for further research -- References -- Chapter Two: Studying the pathophysiology of tic disorders in animal models -- 1. Introduction -- 2. The study of pathophysiology in animal model systems -- 3. Models of cortico-striatal hyperactivity -- 4. Models of elevated dopamine in the basal ganglia -- 5. Local striatal disinhibition -- 6. Interneuron manipulations -- 7. Genetic models -- 8. Conclusion -- References -- Chapter Three: The neural-immune crosstalk in Tourette syndrome: From immunobiology to epistemology -- 1. Introduction -- 2. Immunogenetics of TS -- 2.1. Genomics -- 2.2. Transcriptomics -- 2.3. Epigenetics -- 3. Extra-genetic and environmental predisposing factors -- 3.1. Prenatal period -- 3.2. Delivery/perinatal period -- 3.3. Post-natal life (infections, autoimmune disease, life stressors) -- 4. Immunophenotypes -- 4.1. Systemic immune activation -- 4.2. Autoantibodies -- 4.3. CNS inflammation -- 5. Comorbidities: Confounders or epiphenomena? -- 6. Immune-based therapies.
|
| 505 |
8 |
|
|a 7. Insights from animal studies -- 8. The longstanding debate on the role of group a streptococcus in Tourette syndrome: An epistemological framework -- References -- Chapter Four: Functional connectivity in the Gilles de la Tourette syndrome -- 1. Introduction -- 2. Functional connectivity -- 3. Applications of functional connectivity to TS -- 3.1. Differences in functional connectivity between TS patients and controls -- 3.2. Associations between functional connectivity and clinical, behavioral, and cognitive measures in TS -- 3.2.1. Symptom severity -- 3.2.2. Tic suppression -- 3.2.3. Impulsivity -- 4. Limitations and future directions -- References -- Chapter Five: Perception-action integration in Gilles de la Tourette syndrome -- 1. Introduction -- 2. The role of perceptual processing in Gilles de la Tourette syndrome (GTS) -- 2.1. Premonitory urges -- 2.2. Hypersensitivity to external stimuli -- 2.3. Abnormalities in sensorimotor integration -- 3. Theory of Event Coding (TEC) -- 3.1. The concept of TEC -- 3.2. Neural mechanism underlying TEC -- 4. TEC as an explanatory framework for GTS -- 4.1. Object file processing in GTS -- 4.2. Action file processing in GTS -- 4.3. Event file processing in GTS -- 4.4. A summary of recent findings -- References -- Section V: Current pharmacological treatment of the Gilles de la Tourette syndrome -- Chapter Six: The pharmacological treatment of Tourette syndrome -- 1. Introduction -- 2. Alpha-receptor agonists -- 3. Anticonvulsants -- 4. Dopamine receptor antagonists -- 4.1. D2 receptor antagonists -- 4.2. D1 receptor antagonists -- 5. Dopamine depleting agents -- 6. Muscle relaxants -- 7. Cannabis-based medicine -- 8. Traditional Chinese herbal medicine -- 9. Other medications -- 10. Treatment of Tourette syndrome with comorbid ADHD and OCD -- 11. Decision making on management of tic disorder.
|
| 505 |
8 |
|
|a 12. Conclusions -- Financial disclosure/Conflict of interest -- References -- Chapter Seven: Atypical antipsychotics for treatment of Tourette syndrome -- 1. Background -- 1.1. Natural history -- 1.2. Neurobiology -- 1.3. General treatment considerations -- 2. Methods -- 3. Results -- 3.1. Typical antipsychotics -- 3.2. Atypical antipsychotics -- 3.2.1. Risperidone -- 3.2.2. Aripiprazole -- 3.2.3. Ziprasidone -- 3.2.4. Olanzapine -- 3.2.5. Quetiapine -- 3.2.6. Metoclopramide -- 3.2.7. Clozapine -- 3.3. Newer atypical antipsychotics -- 3.3.1. Iloperidone -- 3.3.2. Asenapine -- 3.3.3. Lurasidone -- 3.3.4. Paliperidone -- 3.4. Substituted benzamides -- 3.4.1. Tiapride -- 3.4.2. Sulpiride -- 3.4.3. Amisulpride -- 4. Conclusions -- References -- Chapter Eight: Ecopipam: A D1 receptor antagonist for the treatment of Tourette syndrome -- 1. Introduction -- 2. Summary of clinical studies of ecopipam in TS -- 2.1. Open label safety and efficacy in adults (ClinicalTrials.gov identifier: NCT01244633) -- 2.2. Double-blind placebo-controlled safety and efficacy in pediatrics (ClinicalTrials.gov identifier: NCT02102698) -- 2.3. Open label extension study -- 2.4. Double-blind, placebo-controlled D1AMOND studies (ClinicalTrials.gov identifier: NCT04007991) and long-term extensio ... -- 3. Discussion -- 4. Summary -- References -- Chapter Nine: Alpha agonists for the treatment of Tourette syndrome -- 1. Pharmacology of alpha agonists in Tourette syndrome -- 2. Pharmacoepidemiology of alpha agonist use for Tourette syndrome -- 3. Review of randomized controlled trials of clonidine and guanfacine for the treatment of Tourette syndrome -- 3.1. Clonidine -- 3.2. Guanfacine -- 3.3. Adverse effects of alpha agonists -- 3.4. Evidence-based recommendations on the use of alpha agonists in people with tics -- References.
|
| 505 |
8 |
|
|a Section VI: Innovative treatments of the Gilles de la Tourette syndrome -- Chapter Ten: Cannabinoids: Possible role in the pathophysiology and therapy of Gilles de la Tourette syndrome -- 1. Introduction -- 2. Role of the endocannabinoid system (ECS) in the pathophysiology of GTS -- 3. Clinical evidence supporting an involvement of the ECS in GTS -- 3.1. Meta-analysis (level I) -- 3.2. Randomized controlled trials (level II) -- 3.2.1. RCTs using dronabinol (THC) -- 3.2.2. RCTs using the endocannabinoid modulator Lu AG06466 (ABX-1431) -- 3.3. Case series and open-label studies (level III) -- 3.4. Case reports (level IV) -- 3.4.1. Case studies in adults and adolescents with GTS -- 3.4.2. Case studies in children with GTS -- 4. Practical clues regarding the use of CBM in patients with GTS and future directions -- References -- Chapter Eleven: Novel potential avenues for the therapy of Tourette syndrome: Cannabinoid- and steroid-based interventions -- 1. Introduction: Pathophysiology and therapy of tic disorders -- 2. Cannabinoids and the endocannabinoid system -- 3. Effects of cannabinoids and cannabis in TS: Current evidence and challenges -- 4. Steroids and steroidogenesis -- 5. Role of steroids in TS: Current evidence and potential mechanisms -- 6. Conclusions and future perspectives -- Acknowledgments -- References -- Chapter Twelve: Non-invasive brain stimulation for the treatment of Tourette�s syndrome -- 1. Introduction -- 2. Basics of transcranial magnetic stimulation (TMS) -- 2.1. Plasticity -- 2.2. Pairing -- 2.3. Precision -- 2.4. How is transcranial magnetic stimulation used in youth? -- 2.5. TMS safety -- 3. Key cortical targets in Tourette�s syndrome -- 4. Application of transcranial magnetic stimulation (TMS) in Tourette�s syndrome -- 4.1. Supplementary motor area -- 4.2. Motor cortex -- 4.3. Parietal cortex -- 5. Conclusions.
|
| 650 |
|
0 |
|a Tourette syndrome
|x Pathophysiology.
|
| 700 |
1 |
|
|a Lavoie, Marc E.
|
| 700 |
1 |
|
|a Cavanna, Andrea E.
|
| 776 |
0 |
8 |
|i Print version:
|z 032391036X
|z 9780323910361
|w (OCoLC)1296530876
|
| 776 |
0 |
8 |
|i Print version:
|t NEUROBIOLOGY OF THE GILLES DE LA TOURETTE SYNDROME AND CHRONIC TICS.
|d [S.l.] : ELSEVIER ACADEMIC PRESS, 2022
|z 032391036X
|w (OCoLC)1296530876
|
| 830 |
|
0 |
|a International review of movement disorders ;
|v v. 4.
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/bookseries/26667878/4
|z Texto completo
|
